PhaseBio Pharmaceuticals EPS Growth (diluted)

EPS Growth (diluted) of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS Growth (diluted) growth rates and interactive chart. Year over year growth in diluted earnings per share.

Highlights and Quick Summary

  • EPS Growth (diluted) for the quarter ending September 29, 2021 was 23.26% (a -40.02% decrease compared to previous quarter)
  • Year-over-year quarterly EPS Growth (diluted) decreased by -114.17%
  • Annual EPS Growth (diluted) for 2020 was -137.06% (a -301.12% decrease from previous year)
  • Annual EPS Growth (diluted) for 2019 was 68.15% (a -106.85% decrease from previous year)
  • Annual EPS Growth (diluted) for 2018 was -995.12% (a 9105.55% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS Growth (diluted) of PhaseBio Pharmaceuticals

Most recent EPS Growth (diluted)of PHAS including historical data for past 10 years.

Interactive Chart of EPS Growth (diluted) of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EPS Growth (diluted) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 23.26% 38.78% -67.31%
2020 -164.1% -115.0% -196.97% -73.33% -137.06%
2019 -50.0% 96.17% 68.15%
2018 -995.12%
2017 -10.81%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.